Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOBILITY: Obinutuzumab in Lupus Nephritis
NCT02550652Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of obinutuzumab in lupus nephritis (LN), sponsored by Roche. Started Nov 2015; status: completed.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT02550652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550652.